Skip to main content
. 2010 Jun;85(6):532–537. doi: 10.4065/mcp.2009.0677

FIGURE 2.

FIGURE 2.

A, Cytogenetics (CG)-based risk stratification of patients with high-risk features by fluorescence in situ hybridization (FISH). When FISH-detected high-risk patients (n=51) are further subdivided into 2 groups based on presence (n=6) or absence (n=45) of high-risk features on CG, median overall survival (OS) is 16 months vs 35 months, respectively. B, CG-based risk stratification of patients with standard (std)-risk features by FISH. When std-risk patients by FISH (n=239) are further subdivided into 2 groups based on presence (n=16) or absence (n=223) of high-risk features on CG, median OS is 37 months vs not reached (NR), respectively. C, FISH-based risk stratification of patients with high-risk features by CG. When high-risk patients by CG (n=22) are further subdivided into 2 groups based on presence (n=6) or absence (n=16) of high-risk features on FISH, median OS is 16 months vs 37 months, respectively. D, FISH-based risk stratification of patients with std-risk features by CG. When std-risk patients by CG (n=268) are further subdivided into 2 groups based on presence (n=45) or absence (n=223) of high-risk features on FISH, median OS is 35 months vs NR, respectively. Rx = therapy.